This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard Kradin, MD; James Kurnick, MD
Massachusetts General Hospital Boston

JAMA. 1987;257(13):1729.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

We read with interest the article by Lotze et al¹ and the accompanying editorial by Dr Moertel.² We share Dr Moertel's concerns about how scientific information is distributed to the public. However, his criticisms have now contributed to an overzealous news media campaign. Dr Moertel's editorial was widely publicized and we fear has succeeded in damaging the reputation of all interleukin 2 (IL-2)-related scientific programs. This is unfortunate, since trials of IL-2 and adoptive cell transfers are under way that are designed to diminish the toxicity of lymphokine-activated killer cell and IL-2 regimens. A phase II immunotherapy trial is under way at the Massachusetts General Hospital in which cultured tumor-infiltrating lymphocytes and relatively low dosages of IL-2 (3x10⁶ U/d) are being administered. Seven patients have been treated in medical beds outside of the intensive care unit and have not experienced hypotension, respiratory distress, or . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?